Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin's lymphoma survivors.
DNA mismatch repair
Hodgkin's lymphoma
cancer survivors
colonoscopy
colorectal neoplasms
Journal
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
ISSN: 1443-1661
Titre abrégé: Dig Endosc
Pays: Australia
ID NLM: 9101419
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
22
04
2021
received:
05
02
2021
accepted:
26
04
2021
pubmed:
1
5
2021
medline:
14
1
2022
entrez:
30
4
2021
Statut:
ppublish
Résumé
Hodgkin's lymphoma (HL) survivors treated with abdominal radiotherapy and/or procarbazine have an increased risk of developing colorectal neoplasia. We evaluated the clinicopathological characteristics and risk factors for developing (advanced) neoplasia (AN) in HL survivors. In all, 101 HL survivors (median age 51 years, median age of HL diagnosis 25 years) underwent colonoscopy and 350 neoplasia and 44 AN (classified as advanced adenomas/serrated lesions or colorectal cancer), mostly right-sided, were detected, as published previously. An average-risk asymptomatic cohort who underwent screening colonoscopy were controls (median age 60 years). Clinicopathological characteristics of AN were evaluated in both groups. Mismatch repair (MMR) status was assessed using immunohistochemistry (MLH1/MSH2/MSH6/PMS2). Logistic regression analysis was performed to evaluate the risk factors for AN in HL survivors, including age at HL diagnosis and interval between HL and colonoscopy. In 101 colonoscopies in HL survivors, AN was primarily classified based on polyp size ≥10 mm, whereas (high-grade)dysplasia was more often seen in AN in controls. An interval between HL diagnosis and colonoscopy >26 years was associated with more AN compared with an interval of <26 years, with an odds ratio for AN of 3.8 (95% confidence interval 1.4-9.1) (p < 0.01). All 39 AN that were assessed were MMR proficient. Colorectal neoplasia in HL survivors differ from average-risk controls; classification AN was primarily based on polyp size (≥10 mm) in HL survivors. Longer follow-up between HL diagnosis and colonoscopy was associated with a higher prevalence of AN in HL survivors.
Sections du résumé
BACKGROUND
BACKGROUND
Hodgkin's lymphoma (HL) survivors treated with abdominal radiotherapy and/or procarbazine have an increased risk of developing colorectal neoplasia.
AIMS
OBJECTIVE
We evaluated the clinicopathological characteristics and risk factors for developing (advanced) neoplasia (AN) in HL survivors.
METHODS
METHODS
In all, 101 HL survivors (median age 51 years, median age of HL diagnosis 25 years) underwent colonoscopy and 350 neoplasia and 44 AN (classified as advanced adenomas/serrated lesions or colorectal cancer), mostly right-sided, were detected, as published previously. An average-risk asymptomatic cohort who underwent screening colonoscopy were controls (median age 60 years). Clinicopathological characteristics of AN were evaluated in both groups. Mismatch repair (MMR) status was assessed using immunohistochemistry (MLH1/MSH2/MSH6/PMS2). Logistic regression analysis was performed to evaluate the risk factors for AN in HL survivors, including age at HL diagnosis and interval between HL and colonoscopy.
RESULTS
RESULTS
In 101 colonoscopies in HL survivors, AN was primarily classified based on polyp size ≥10 mm, whereas (high-grade)dysplasia was more often seen in AN in controls. An interval between HL diagnosis and colonoscopy >26 years was associated with more AN compared with an interval of <26 years, with an odds ratio for AN of 3.8 (95% confidence interval 1.4-9.1) (p < 0.01). All 39 AN that were assessed were MMR proficient.
CONCLUSIONS
CONCLUSIONS
Colorectal neoplasia in HL survivors differ from average-risk controls; classification AN was primarily based on polyp size (≥10 mm) in HL survivors. Longer follow-up between HL diagnosis and colonoscopy was associated with a higher prevalence of AN in HL survivors.
Identifiants
pubmed: 33928678
doi: 10.1111/den.14004
pmc: PMC9290704
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
163-170Subventions
Organisme : Dutch Digestive Disease Foundation
ID : FP 14-04
Informations de copyright
© 2021 The Authors. Digestive Endoscopy published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.
Références
Nature. 2019 Oct;574(7779):532-537
pubmed: 31645730
JAMA. 2008 Dec 17;300(23):2765-78
pubmed: 19088354
J Clin Oncol. 2007 Apr 20;25(12):1489-97
pubmed: 17372278
J Pathol. 2012 Apr;226(5):764-74
pubmed: 22081473
Dig Dis Sci. 2018 Sep;63(9):2451-2455
pubmed: 29855768
Gut. 2017 Jan;66(1):97-106
pubmed: 26475632
Cancer. 2004 Sep 15;101(6):1463-72
pubmed: 15368334
Cancer. 2019 Mar 15;125(6):990-999
pubmed: 30561773
Nat Genet. 2019 Dec;51(12):1732-1740
pubmed: 31740835
Eur J Gastroenterol Hepatol. 2018 Nov;30(11):1337-1343
pubmed: 30085964
BMC Cancer. 2017 Feb 7;17(1):112
pubmed: 28173773
J Clin Oncol. 2000 Feb;18(3):498-509
pubmed: 10653865
Am J Gastroenterol. 1995 Mar;90(3):353-65
pubmed: 7872270
Gastroenterology. 2012 Apr;142(4):762-72
pubmed: 22245665
Gut. 2018 Mar;67(3):447-455
pubmed: 29439113
Mod Pathol. 2018 Oct;31(10):1608-1618
pubmed: 29884888
Colorectal Dis. 2020 Feb;22(2):154-160
pubmed: 31541529
Genes (Basel). 2019 Jan 10;10(1):
pubmed: 30634664
Lancet. 2014 Apr 26;383(9927):1490-1502
pubmed: 24225001
N Engl J Med. 2015 Dec 24;373(26):2499-511
pubmed: 26699166
Br J Cancer. 2017 Jul 25;117(3):306-314
pubmed: 28632726
J Clin Oncol. 2002 Aug 15;20(16):3484-94
pubmed: 12177110
Am J Epidemiol. 2015 Jun 1;181(11):832-45
pubmed: 25888582
Gastroenterology. 2008 Feb;134(2):388-95
pubmed: 18242207
Lancet Oncol. 2012 Jan;13(1):55-64
pubmed: 22088831
Ann Intern Med. 2012 Jun 5;156(11):757-66, W-260
pubmed: 22665813
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e383-90
pubmed: 22284034
Gut. 2017 Oct;66(10):1797-1801
pubmed: 27411369
J Clin Oncol. 2012 Jul 10;30(20):2552-8
pubmed: 22665546